Elicio Therapeutics initiated with a Buy at JonesResearch

JonesResearch analyst Soumit Roy initiated coverage of Elicio Therapeutics (ELTX) with a Buy rating and $9 price target Elicio’s off-the-shelf cancer vaccine candidate is “probably given the best possible chance to succeed,” the analyst tells investors in a research note. The firm says the company’s AMP platform delivers neoantigen peptides to the lymph nodes to generate better immune response, a hot tumor type in post-surgical setting but with biomarker positive status.